Number of shares and votes in Medivir

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the
number of shares and votes in Medivir has changed as a result of redemption of
share under the voluntary redemption programme resolved at the extraordinary
general meeting on 20 November 2014. The new number of shares has been
registered with the Swedish Companies Registration Office during March 2015.

Today, the last trading day of the month, the total number of outstanding shares
in Medivir are 26,966,037, whereof 606,358 series A shares and 26,359,679 series
B shares, and the total number of votes amounts to 32,423,259 votes.

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580.

Medivir is required under the Financial Instruments Trading Act to make the
information in this press release public. The information was submitted for
publication at 8.30 CET on 31 March 2015.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm
Mid Cap List.